Key facts
- This page summarizes Michael Grissinger's Form 3 filing for Aprea Therapeutics, Inc. (APRE).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 May 2022, 16:15.
Michael Grissinger - 16 May 2022 Form 3 Insider Report for Aprea Therapeutics, Inc. (APRE)
- Reporting relationship
- Director
- Issuer ticker
- APRE
- Reported as of
- 16 May 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 26 May 2022, 16:15:59 UTC
- Next SEC filing
- 01 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott M. Coiante, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Grissinger filed Form 3 for Aprea Therapeutics, Inc. (APRE) on 26 May 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APRE
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 16 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 72,638
- Exercise price
- $0.4400
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Exhibit 24 - Power of Attorney